CY1125076T1 - Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτων - Google Patents
Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτωνInfo
- Publication number
- CY1125076T1 CY1125076T1 CY20221100075T CY221100075T CY1125076T1 CY 1125076 T1 CY1125076 T1 CY 1125076T1 CY 20221100075 T CY20221100075 T CY 20221100075T CY 221100075 T CY221100075 T CY 221100075T CY 1125076 T1 CY1125076 T1 CY 1125076T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tgfb1
- isoform
- selective inhibitors
- disclosed
- antigen
- Prior art date
Links
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Στο κείμενο αποκαλύπτονται μονοκλωνικά αντισώματα και αντιγονοδεσμεύοντα θραύσματα αυτών, ικανά να αναστείλουν εκλεκτικά τον TGFβ1 με υψηλή ισχύ. Επίσης αποκαλύπτονται σχετικές συνθέσεις, μέθοδοι και θεραπευτική χρήση.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862696752P | 2018-07-11 | 2018-07-11 | |
US201862696774P | 2018-07-11 | 2018-07-11 | |
US201862718196P | 2018-08-13 | 2018-08-13 | |
US201862722081P | 2018-08-23 | 2018-08-23 | |
US201862737534P | 2018-09-27 | 2018-09-27 | |
US201862757917P | 2018-11-09 | 2018-11-09 | |
US201862758180P | 2018-11-09 | 2018-11-09 | |
US201962810263P | 2019-02-25 | 2019-02-25 | |
US201962827552P | 2019-04-01 | 2019-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125076T1 true CY1125076T1 (el) | 2023-06-09 |
Family
ID=67437706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100075T CY1125076T1 (el) | 2018-07-11 | 2022-01-28 | Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτων |
Country Status (13)
Country | Link |
---|---|
US (2) | US11130803B2 (el) |
EP (2) | EP3677278B1 (el) |
CY (1) | CY1125076T1 (el) |
DK (1) | DK3677278T3 (el) |
ES (1) | ES2905160T3 (el) |
HR (1) | HRP20212034T1 (el) |
HU (1) | HUE056501T2 (el) |
LT (1) | LT3677278T (el) |
MA (1) | MA52165A (el) |
PL (1) | PL3677278T3 (el) |
PT (1) | PT3677278T (el) |
RS (1) | RS62914B1 (el) |
SI (1) | SI3677278T1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4121163A1 (en) * | 2020-03-19 | 2023-01-25 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
WO2022256723A2 (en) * | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
US20230144192A1 (en) * | 2021-11-01 | 2023-05-11 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
CN114236137A (zh) * | 2021-12-17 | 2022-03-25 | 中山大学·深圳 | 一种转化生长因子β的体外检测试剂盒及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
DE60137421D1 (de) | 2000-06-29 | 2009-03-05 | Abbott Lab | Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung |
JP4653660B2 (ja) | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | TGF−β活性化制御領域の切断面を認識する抗体 |
BRPI0607639B1 (pt) | 2005-02-08 | 2022-04-05 | Genzyme Corporation | Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
ES2663946T3 (es) | 2011-11-14 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A |
US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
EP3139957A4 (en) | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
US10723793B2 (en) | 2015-06-12 | 2020-07-28 | Ludwig Institute For Cancer Research, Ltd. | TGF-β3 specific antibodies and methods and uses thereof |
EP3324996A4 (en) | 2015-07-22 | 2019-04-17 | Scholar Rock, Inc. | GDF11 BINDING PROTEINS AND USES THEREOF |
LT3350220T (lt) | 2015-09-15 | 2021-09-27 | Scholar Rock, Inc. | Anti pro/latentinio miostatino antikūnai ir jų panaudojimas |
PL3365368T3 (pl) | 2016-03-11 | 2023-08-21 | Scholar Rock, Inc. | Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie |
SG11201900200XA (en) | 2016-07-14 | 2019-02-27 | Scholar Rock Inc | Tgfb antibodies, methods, and uses |
WO2018129329A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
EP3658583A1 (en) | 2017-07-28 | 2020-06-03 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
MX2021000347A (es) | 2018-07-11 | 2021-04-19 | Scholar Rock Inc | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. |
WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
-
2019
- 2019-07-11 PL PL19185896T patent/PL3677278T3/pl unknown
- 2019-07-11 US US16/509,068 patent/US11130803B2/en active Active
- 2019-07-11 HU HUE19185896A patent/HUE056501T2/hu unknown
- 2019-07-11 MA MA052165A patent/MA52165A/fr unknown
- 2019-07-11 DK DK19185896.8T patent/DK3677278T3/da active
- 2019-07-11 LT LTEP19185896.8T patent/LT3677278T/lt unknown
- 2019-07-11 SI SI201930143T patent/SI3677278T1/sl unknown
- 2019-07-11 ES ES19185896T patent/ES2905160T3/es active Active
- 2019-07-11 RS RS20220099A patent/RS62914B1/sr unknown
- 2019-07-11 HR HRP20212034TT patent/HRP20212034T1/hr unknown
- 2019-07-11 EP EP19185896.8A patent/EP3677278B1/en active Active
- 2019-07-11 PT PT191858968T patent/PT3677278T/pt unknown
- 2019-07-11 EP EP21206768.0A patent/EP4019046A1/en active Pending
-
2021
- 2021-08-19 US US17/406,400 patent/US20220064275A1/en active Pending
-
2022
- 2022-01-28 CY CY20221100075T patent/CY1125076T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI3677278T1 (sl) | 2022-01-31 |
US11130803B2 (en) | 2021-09-28 |
DK3677278T3 (da) | 2022-01-10 |
US20200079840A1 (en) | 2020-03-12 |
MA52165A (fr) | 2021-06-02 |
US20220064275A1 (en) | 2022-03-03 |
EP3677278B1 (en) | 2021-11-10 |
RS62914B1 (sr) | 2022-03-31 |
ES2905160T3 (es) | 2022-04-07 |
HUE056501T2 (hu) | 2022-02-28 |
PL3677278T3 (pl) | 2022-02-28 |
EP3677278A1 (en) | 2020-07-08 |
EP4019046A1 (en) | 2022-06-29 |
PT3677278T (pt) | 2022-02-03 |
HRP20212034T1 (hr) | 2022-04-01 |
LT3677278T (lt) | 2022-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125076T1 (el) | Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτων | |
CO2021000419A2 (es) | Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos | |
BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
WO2020014473A8 (en) | TGFβ1 INHIBITORS AND USE THEREOF | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
EA202190315A1 (ru) | Химерные антигенные рецепторы со специфичностью к bcma и их применение | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
CO2021009129A2 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
EA201991876A1 (ru) | Антитела против фактора d и их применения | |
MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
EA202091295A1 (ru) | Препарат | |
MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
CR20230581A (es) | Anticuerpos anti-CCR8 y usos de los mismos | |
CR20230087A (es) | Anticuerpos anti-notch2 y métodos de uso |